Atrial fibrillation management strategies and early mortality after myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction (VALIANT) trial

Kent R. Nilsson, Sana M. Al-Khatib, Yi Zhou, Karen Pieper, Harvey D. White, Aldo P. Maggioni, Lars Kober, Christopher B. Granger, Eldrin F. Lewis, John J.V. McMurray, Robert M. Califf, Eric J. Velazquez

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Objective: The management of patients with atrial fibrillation (AF) following a myocardial infarction (MI) remains uncertain. This study compared a rate control strategy to an anti-arrhythmic-based rhythm control strategy for the treatment of AF following myocardial infarction. Design, setting and patients: We studied 1131 patients with AF after MI who were enrolled in the Valsartan in Acute Myocardial Infarction Trial (VALIANT). We classified patients into those treated with a rhythm control strategy (n=371) and those treated with a rate control strategy (n=760). Main outcomes measures: Using Cox models, we compared the two groups with respect to both death and stroke during two different time periods after randomisation for which data collection had been prespecified: 0e45 days and 45e1096 days. Results: After adjustment, a rhythm control strategy was found to be associated with increased early mortality (0-45 days: HR: 1.9, 95% CI 1.2 to 3.0, p=0.004) but not late mortality (45-1096 days: HR 1.1, 95% CI 0.9 to 1.4, p=0.45). No difference was observed in the incidence of stroke (0-45 days: HR 1.2, 95% CI 0.4 to 3.7, p=0.73; 45-1096 days: HR 0.6, 95% CI 0.3 to 1.3, p=0.21). Conclusions: In patients with AF after an MI, an antiarrhythmic drug-based rhythm control strategy is associated with excess 45-day mortality compared with a rate control strategy, but is not associated with increased mortality outside of the immediate peri-infarct period. These results potentially identify a patient population in whom the use of anti-arrhythmic drug therapy may portend an increased risk of death.

Original languageEnglish (US)
Pages (from-to)838-842
Number of pages5
JournalHeart
Volume96
Issue number11
DOIs
StatePublished - Jun 2010
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Atrial fibrillation management strategies and early mortality after myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction (VALIANT) trial'. Together they form a unique fingerprint.

Cite this